Skip to main content
Top
Published in: Clinical Pharmacokinetics 5/2010

01-05-2010 | Original Research Article

Kinetics of Imipenem Distribution into the Peritoneal Fluid of Patients with Severe Peritonitis Studied by Microdialysis

Authors: Claire Dahyot-Fizelier, Sandrine Lefeuvre, Leila Laksiri, Sandrine Marchand, Ronald J. Sawchuk, Dr William Couet, Olivier Mimoz

Published in: Clinical Pharmacokinetics | Issue 5/2010

Login to get access

Abstract

Background and Objectives

A microdialysis study of meropenem distribution in the peritoneal fluid of patients with peritonitis has suggested that there is significant peripheral drug degradation. The aims of the present study were to investigate the plasma and peritoneal fluid pharmacokinetics of imipenem, a relatively unstable antibacterial, in patients with severe peritonitis, and to relate measured unbound concentrations to the minimum inhibitory concentrations required for susceptible and intermediately susceptible bacteria.

Methods

Microdialysis catheters were placed into the peritoneal cavity through peritoneal drains in nine critically patients. Imipenem concentrations in plasma and in peritoneal fluid were analysed using compartmental modelling.

Results

A model that considered elimination from a peripheral compartment described the data and was used to simulate steady-state concentration profiles in plasma and peritoneal fluid during various dosing regimens. Using recommended dosing regimens (500 mg every 6 hours, 1000 mg every 8 hours and 1000 mg every 6 hours), simulated unbound peritoneal fluid concentrations of imipenem in patients with severe peritonitis reached values sufficient for antibacterial effects against susceptible bacteria. However, the adequacy of regimens in patients with severe peritonitis whose infections involve intermediately susceptible bacteria is questionable.

Conclusion

The results of this study are consistent with those previously observed with meropenem and confirm the usefulness of microdialysis for assessment of peritoneal fluid distribution of antibacterials.
Literature
1.
go back to reference Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time. Crit Care Med 1998 Dec; 26(12): 2078–86PubMedCrossRef Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time. Crit Care Med 1998 Dec; 26(12): 2078–86PubMedCrossRef
2.
go back to reference Hutchins RR, Gunning MP, Lucas DN, et al. Relaparotomy for suspected intraperitoneal sepsis after abdominal surgery. World J Surg 2004 Feb; 28(2): 137–41PubMedCrossRef Hutchins RR, Gunning MP, Lucas DN, et al. Relaparotomy for suspected intraperitoneal sepsis after abdominal surgery. World J Surg 2004 Feb; 28(2): 137–41PubMedCrossRef
3.
go back to reference Koperna T, Schulz F. Relaparotomy in peritonitis: prognosis and treatment of patients with persisting intraabdominal infection. World J Surg 2000 Jan; 24(1): 32–7PubMedCrossRef Koperna T, Schulz F. Relaparotomy in peritonitis: prognosis and treatment of patients with persisting intraabdominal infection. World J Surg 2000 Jan; 24(1): 32–7PubMedCrossRef
4.
go back to reference Pacelli F, Doglietto GB, Alfieri S, et al. Prognosis in intra-abdominal infections: multivariate analysis on 604 patients. Arch Surg 1996 Jun; 131(6): 641–5PubMedCrossRef Pacelli F, Doglietto GB, Alfieri S, et al. Prognosis in intra-abdominal infections: multivariate analysis on 604 patients. Arch Surg 1996 Jun; 131(6): 641–5PubMedCrossRef
5.
go back to reference Billing A, Frohlich D, Schildberg FW. Prediction of outcome using the Mannheim Peritonitis Index in 2003 patients. Peritonitis Study Group. Br J Surg 1994 Feb; 81(2): 209–13 Billing A, Frohlich D, Schildberg FW. Prediction of outcome using the Mannheim Peritonitis Index in 2003 patients. Peritonitis Study Group. Br J Surg 1994 Feb; 81(2): 209–13
6.
go back to reference Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003 Oct 15; 37(8): 997–1005PubMedCrossRef Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003 Oct 15; 37(8): 997–1005PubMedCrossRef
7.
go back to reference Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc 1999 Apr; 74(4): 420–34PubMedCrossRef Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc 1999 Apr; 74(4): 420–34PubMedCrossRef
8.
go back to reference Clissold SP, Todd PA, Campoli-Richards DM. Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1987 Mar; 33(3): 183–241PubMedCrossRef Clissold SP, Todd PA, Campoli-Richards DM. Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1987 Mar; 33(3): 183–241PubMedCrossRef
9.
go back to reference Johnson CC, Baldessarre J, Levison ME. Peritonitis: update on pathophysiology, clinical manifestations, and management. Clin Infect Dis 1997 Jun; 24(6): 1035–145; quiz 1046-7PubMedCrossRef Johnson CC, Baldessarre J, Levison ME. Peritonitis: update on pathophysiology, clinical manifestations, and management. Clin Infect Dis 1997 Jun; 24(6): 1035–145; quiz 1046-7PubMedCrossRef
10.
go back to reference Karjagin J, Lefeuvre S, Oselin K, et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther 2008 Mar; 83(3): 452–9PubMedCrossRef Karjagin J, Lefeuvre S, Oselin K, et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther 2008 Mar; 83(3): 452–9PubMedCrossRef
11.
go back to reference Dahyot C, Marchand S, Bodin M, et al. Application of basic pharmacokinetic concepts to analysis of microdialysis data: illustration with imipenem muscle distribution. Clin Pharmacokinet 2008; 47(3): 181–9PubMedCrossRef Dahyot C, Marchand S, Bodin M, et al. Application of basic pharmacokinetic concepts to analysis of microdialysis data: illustration with imipenem muscle distribution. Clin Pharmacokinet 2008; 47(3): 181–9PubMedCrossRef
12.
go back to reference Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet 1995 Apr; 28(4): 275–86PubMedCrossRef Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet 1995 Apr; 28(4): 275–86PubMedCrossRef
13.
go back to reference Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003 Apr; 29(4): 530–8PubMed Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003 Apr; 29(4): 530–8PubMed
14.
go back to reference Bouw MR, Hammarlund-Udenaes M. Methodological aspects of the use of a calibrator in in vivo microdialysis: further development of the retrodialysis method. Pharm Res 1998 Nov; 15(11): 1673–9PubMedCrossRef Bouw MR, Hammarlund-Udenaes M. Methodological aspects of the use of a calibrator in in vivo microdialysis: further development of the retrodialysis method. Pharm Res 1998 Nov; 15(11): 1673–9PubMedCrossRef
15.
go back to reference Clinical and Laboratory Standards Institute [CLSI]. Performance standards for antimicrobial susceptibility testing: approved standard. 9th ed. Wayne (PA): CLSI, 2006 Clinical and Laboratory Standards Institute [CLSI]. Performance standards for antimicrobial susceptibility testing: approved standard. 9th ed. Wayne (PA): CLSI, 2006
16.
go back to reference Fukasawa M, Sumita Y, Harabe ET, et al. Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Agents Chemother 1992 Jul; 36(7): 1577–9PubMedCrossRef Fukasawa M, Sumita Y, Harabe ET, et al. Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Agents Chemother 1992 Jul; 36(7): 1577–9PubMedCrossRef
17.
go back to reference Lefeuvre S, Marchand S, Lamarche I, et al. Microdialysis study of imipenem distribution in the intraperitoneal fluid of rats with or without experimental peritonitis. Antimicrob Agents Chemother 2006 Jan; 50(1): 34–7PubMedCrossRef Lefeuvre S, Marchand S, Lamarche I, et al. Microdialysis study of imipenem distribution in the intraperitoneal fluid of rats with or without experimental peritonitis. Antimicrob Agents Chemother 2006 Jan; 50(1): 34–7PubMedCrossRef
18.
go back to reference Lefeuvre S, Marchand S, Pariat C, et al. Microdialysis study of imipenem distribution in the peritoneal fluid of rats with experimental acute pancreatitis. Antimicrob Agents Chemother 2008 Apr; 52(4): 1516–8PubMedCrossRef Lefeuvre S, Marchand S, Pariat C, et al. Microdialysis study of imipenem distribution in the peritoneal fluid of rats with experimental acute pancreatitis. Antimicrob Agents Chemother 2008 Apr; 52(4): 1516–8PubMedCrossRef
19.
go back to reference Mouton JW, Touzw DJ, Horrevorts AM, et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000 Sep; 39(3): 185–201PubMedCrossRef Mouton JW, Touzw DJ, Horrevorts AM, et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000 Sep; 39(3): 185–201PubMedCrossRef
20.
go back to reference Koppel BS, Hauser WA, Politis C, et al. Seizures in the critically ill: the role of imipenem. Epilepsia 2001 Dec; 42(12): 1590–3PubMedCrossRef Koppel BS, Hauser WA, Politis C, et al. Seizures in the critically ill: the role of imipenem. Epilepsia 2001 Dec; 42(12): 1590–3PubMedCrossRef
Metadata
Title
Kinetics of Imipenem Distribution into the Peritoneal Fluid of Patients with Severe Peritonitis Studied by Microdialysis
Authors
Claire Dahyot-Fizelier
Sandrine Lefeuvre
Leila Laksiri
Sandrine Marchand
Ronald J. Sawchuk
Dr William Couet
Olivier Mimoz
Publication date
01-05-2010
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 5/2010
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/11319370-000000000-00000

Other articles of this Issue 5/2010

Clinical Pharmacokinetics 5/2010 Go to the issue